Table 3.
Clinical and parasitological outcomes by site and treatment group
| Mutengene | Yaounde | Garoua | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | group | SPAQ | SP | AQ | SPAQ | SP | AQ | SPAQ | SP | AQ |
| ETF | 4 | 14 | 3 | 0 | 8 | 1 | 3 | 10 | 10 | |
| LCF | 2 | 7 | 4 | 2 | 12 | 4 | 2 | 5 | 1 | |
| LPF | 6 | 11 | 6 | 10 | 12 | 8 | 6 | 7 | 8 | |
| ACPR, D14 (PCR corrected) | 82.5% | 75.3% | 88.3% | 82.3% | 88.0% | 86.3% | 81.7% | 71.0% | 72.0% | |
| ACPR, D28 (PCR corrected) | 81.9% | 62.5% | 79.2% | 76.2% | 67.5% | 80.3% | 80.9% | 70.1% | 71.2% | |
| Gametocyte | D3 | 1 | 10 | 3 | 9 | 7 | 4 | 0 | 1 | 1 |
| Carriage(n) | D7 | 2 | 11 | 4 | 7 | 14 | 6 | 0 | 2 | 1 |
| D14 | 0 | 6 | 0 | 3 | 16 | 0 | 0 | 1 | 0 | |
| D28 | 0 | 1 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | |
| % | 2.4% | 13.9% | 5.0% | 8.9% | 14.5% | 7.1% | 0.0% | 2.9% | 1.4% | |
A, B, C, were groups to which independently at each site drugs were randomly assigned. SP- Sulphadoxine-pyrimethamine, AQ - Amodiaquine, SPAQ- combination of AQ and SP. ETF - Early Treatment Failure, LCF - Late Clinical Failure, LPF- Late Parastological Failure, ACPR - Adequate Clinical and Parasitological Response.